Tag: Vivo
-
Fundamental Hype: Vivo Cannabis (VIVO.V) doubles stock price in no time flat: But why?
Way way waaaay back, when Equity.Guru was a young pup and the cannabis industry was still being built on fumes of promise, Vivo Cannabis (VIVO.V) – formerly AbCann – was an industry darling. For a hot minute, anyway. The reasons why Vivo fell off the table and not only grew out of favour, but almost…
-
Marijuana update: No, the market isn’t getting killed… we’re just not rewarding bullshit anymore
Top tip: You guys out there whining about ‘the market’ being down are finding excuses for the wrong problem. Folks be running about with their hair on fire right now, pointing to a sky that for sure is falling because a few of their favourite weed stocks have come off absurd highs and what if…
-
Too professional: Pure Global (PURE.V) and the companies discounted because they’re actually building businesses
Had a conversation on the phone with Stephen Pynn, VP of Corporate Devs at Pure Global (PURE.V) this week that got me thinking. Pure has had an up and down run since landing on the public markets in July of this year. It ebbs and flows like the tides, never getting really beat up, but also…
-
Canopy Growth Corp (WEED.T) has $5 billion to buy something: What’s on the list?
I’ve written this story three times in as many days, because every time I get to the bottom and am ready to post, the valuations of everything seem to have changed. So, to hell with it: I’m sticking the landing on this version. Time for Equity.Guru to veer off market news and into fantasy sports…
-
Aurora (ACB.T) breaks $7 support; ABcann (ABCN.V) acquires Canna Farms & launches sexy rec brand
Today Aurora Cannabis (ACB.T) closed at $6.81 CAD on 20.6 million shares traded. The is the first time Aurora has closed below the $7 support level since December 7th, 2017. It bounced off of that support level in February, April, and May, going on trough-to-peak runs of 59%, 29.3% and 46% respectively, each time it…
-
ABcann (ABCN.V) founder sells 800,000 shares – then resigns
There are legitimate reasons to tell a delinquent off-spring, “I dislike you”. But it’s still something you should never do. We have the same opinion about company insiders off-loading high volumes of a micro-cap stock. It’s crappy behavior. Shareholders (like children) expect stronger leadership. ABcann Global (ABCN.V) is involved in the production of pharmaceutical-grade cannabis…
-
Stop saying ‘this is a good time to buy’.. it’s not. It’s a crash. Back away from the keyboard.
Jesus crap on a pogo stick, you people never learn. So last week, right when we said it would, the weed market began to prolapse. And on social media all I heard was, “This is a great time to buy on dips.” Early this week, it kept rolling downhill, and on social media all I…
-
Called it: Invictus MD Strategies (IMH.V), Abcann (ABCN.V) and DOJA (DOJA.C) defy weed market gravity
Invictus MD Strategies (IMH.V) announced today that it has delivered 120kg of cannabis to Canopy Growth Corp (WEED.T), its first B2B delivery of flower, to be sold through that company’s CraftGrow line alongside PEI’s Island Garden. “On behalf of the Canopy Growth team, I want to congratulate the AB Labs team for achieving this milestone,”…
-
Is ABcann (ABCN.V) good or lucky?
Amidst the rolling waves of dull grey days – have you ever had a brilliant shiny one where it seemed the world was inexplicably fond of you? ABcann (ABCN.V) – a seller of pharmaceutical-grade cannabis – just had a day like that. On January 22, 2018, the intra-day chart looked like this: Normally, when a…
-
ABcann Medical (ABCN.V) talks and walks like a pharmaceutical company
On October 17, 2017 Abcann Medical (ABCN.V) announced the appointment of Paul Lucas as Chair of its Board. Mr. Lucas is the former CEO of GlaxoSmithKline Canada (1994-2012). GlaxoSmithKline (GSK.NYSE) is a venerable UK pharmaceutical company launched in 1848 with laxative pills. After successfully loosening the bowels of Queen Victoria and Oscar Wilde – it…
